SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors react to the company's WWDC keynote, which unveiled new 'Apple Intelligence' features and partnerships with Google and Nvidia. While some community members are excited about the AI integration and ecosystem expansion, many others are selling into the news, citing concerns over delayed rollouts in key markets and a perceived lack of original innovation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened community discussion as traders scrutinize Phase 3 trial timelines and potential acquisition catalysts, while closely comparing the tolerability profile of VK2735 against competitors like Eli Lilly's Reta. Investors are specifically focused on the upcoming maintenance trial data as a critical inflection point that could solidify the drug's best-in-class potential and drive a valuation re-rating.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened trading volume and sentiment following reports of a significant new AI chip partnership with ByteDance, which investors view as a key strategic move to diversify its revenue beyond mobile handsets. The community is actively debating whether this deal validates the company's shift toward data center and edge AI infrastructure or if the stock remains susceptible to volatility and sector-wide sentiment shifts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following the announcement of a massive 15-year AI data center lease with a hyperscaler, a move that community members are highlighting as a major validator of the company's long-term revenue visibility and growth strategy. Investors are actively discussing the stock's significant contracted backlog and the potential for a long-term re-rating, with many viewing recent volatility as a base-building opportunity ahead of further momentum.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently navigating intense market headwinds, including clinical setbacks with its next-generation drug candidate and increasing competition from rival obesity treatments. Despite these challenges, the community is focused on the strong prescription volume of its oral semaglutide and potential opportunities for long-term growth as the company works to solidify its position in the evolving weight-management sector.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as community members weigh the potential antitrust approval of its major acquisition of Warner Bros. Discovery against ongoing regulatory scrutiny. Discussions are largely focused on the potential impact of this consolidation on the broader media landscape, future corporate strategy, and the stock's recent price volatility.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors monitor ongoing federal rescheduling developments and evaluate the impact of new regulations on the broader cannabis market. The community remains focused on the company's strong balance sheet and cash flow, with active debate regarding its potential path toward major exchange uplisting.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is facing intense downward pressure and high volatility as investors react to rapid C-suite turnover, including the recent departure of its CRO and the appointment of a new CFO. While some in the community see the current price as an oversold buying opportunity with strong cash reserves, others are expressing significant frustration with management's performance and the lack of a major catalyst to break the stock's persistent downtrend.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors anticipate key 52-week clinical data and potential M&A activity following a recent supply agreement with Vetter Pharma. Community discussions are heavily focused on the company's status as a high-value acquisition target and the upcoming presentation of trial data at major industry conferences.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is seeing heightened volatility as investors debate the timing of a long-anticipated FCC Notice of Proposed Rulemaking (NPRM) for its 900 MHz spectrum. While the community is currently reacting to legislative noise and agenda delays, the core conversation remains anchored in the company's valuation as a scarce PNT and spectrum asset that could attract significant interest from major telecommunications and satellite bidders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials

Equity

Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.


A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Key PointsZealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients...

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.

Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro

NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare...

Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?

NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.

Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs

Novo Nordisk reported positive diabetes and weight-loss data, advanced zenagamtide plans, and topped 3 million Wegovy pill prescriptions.read more...

Bullish Sentiment

Investors are hyper-focused on accelerating prescription numbers for Wegovy and the ongoing explosive growth of the oral weight-loss drug market.

Contrasting data readouts from competitors like LLY and VKTX are fueling intense debate over which pharma pipeline currently holds the winning efficacy.

Traders are clashing over whether the current price represents a deep-value defensive opportunity or a broken, underperforming asset.

Speculation is swirling around potential partnerships with small-cap firms to solve side effects and address muscle preservation for patients.

Market participants are weighing the prospects of a broader rotation from volatile AI tech stocks into established, defensive healthcare names.

Current Price	$41.02
Prev Close	$42.96
Open	$42.22
Dividend Yield	2.53%
50-Day Moving Average	$41.75
Beta	0.94
Avg. Volume	15.12M
PE Ratio	10.07

52-Week High	$81.44
52-Week Low	$35.12
Market Capitalization	$144.74B
EPS (Annual)	$3.49
Price to Book	6.10
Revenue Per Employee	$679,358.45

NVONovo Nordisk A/S

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News